#52169
#52170
Re: Farmas USA
#52171
Re: Farmas USA
#52172
Re: Farmas USA
#52173
Re: Farmas USA
#52174
Re: Farmas USA
ARNA
La noticia es de primera hora...
Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that data from the Phase 3 clinical trial program for BELVIQ® (lorcaserin HCl) CIV will be presented at the American College of Clinical Pharmacy (ACCP) Annual Meeting taking place October 12-15, 2014, in Austin, Texas.
#52175
Re: Farmas USA
#52176